Evidence map›Paper›PMID 29427412›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2018

Galectin-3 Interacts with the CHI3L1 Axis and Contributes to Hermansky-Pudlak Syndrome Lung Disease.

Yang Zhou, Chuan Hua He, Daniel S Yang, Tung Nguyen, Yueming Cao, Suchitra Kamle, Chang-Min Lee, Bernadette R Gochuico, William A Gahl, Barry S Shea and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 60 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Insights into the Pathogenesis of Pulmonary Fibrosis from Genetic Diseases.American journal of respiratory cell and molecular biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yang ZhouDepartment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912; jack_elias@brown.edu yang_zhou@brown.edu.ORCID 0000-0001-6867-6443
Chuan Hua HeDepartment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912.
Daniel S YangDepartment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912.
Tung NguyenDepartment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912.
Yueming CaoDepartment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912.ORCID 0000-0003-4014-7093
Suchitra KamleDepartment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912.
Chang-Min LeeDepartment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912.ORCID 0000-0002-0130-6947
Bernadette R GochuicoMedical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892.
William A GahlMedical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892.
Barry S SheaDivision of Pulmonary, Critical Care and Sleep Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI 02903; and.ORCID 0000-0002-3205-026X
Chun Geun LeeDepartment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912.
Jack A EliasDepartment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912; jack_elias@brown.edu yang_zhou@brown.edu.ORCID 0000-0002-3124-8557
Brown University · USNational Institutes of Health · US

Funding

Human Biochemical GeneticsZIAHG000215 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI GAHL, WILLIAM · 2009 to 2025
$72.6M
Tracking and Evaluation CoreU54GM115677 · NIGMS · BROWN UNIVERSITY · PI TUULI, METHODIUS GAMUO · 2016 to 2025
$45.0M
Uncoupling of IL-1 beta and VEGF-A Crosstalk Contributes to Impaired Arteriogenesis Response to Ischemia in Chronic Diabetes MellitusP20GM103652 · NIGMS · OCEAN STATE RESEARCH INSTITUTE, INC. · PI HARRINGTON, ELIZABETH O · 2013 to 2022
$21.3M
YKL-40 in Idiopathic Pulmonary Fibrosis and Kidney TransplantationU01HL108638 · NHLBI · YALE UNIVERSITY · PI ELIAS, JACK A · 2011 to 2014
$2.6M
BRP-39/YKL-40 in Th2 Inflammation and AsthmaR01HL093017 · NHLBI · YALE UNIVERSITY · PI ELIAS, JACK A · 2010 to 2013
$1.6M
Chitinase1 as a Biomarker and Therapeutic Target in Scleroderma Lung DiseaseR01HL115813 · NHLBI · BROWN UNIVERSITY · PI LEE, CHUN GEUN · 2014 to 2017
$1.5M
NHLBI NIH HHS R01 HL093017NHLBI NIH HHS R01 HL115813NHLBI NIH HHS U01 HL108638NIGMS NIH HHS P20 GM103652NIGMS NIH HHS U54 GM115677
6 · The paper itself

Abstract

Hermansky-Pudlak syndrome (HPS) comprises a group of inherited disorders caused by mutations that alter the function of lysosome-related organelles. Pulmonary fibrosis is the major cause of morbidity and mortality in HPS-1 and HPS-4 patients. However, the mechanisms that underlie the exaggerated injury and fibroproliferative repair responses in HPS have not been adequately defined. In particular, although Galectin-3 (Gal-3) is dysregulated in HPS, its roles in the pathogenesis of HPS have not been adequately defined. In addition, although chitinase 3-like 1 (CHI3L1) and its receptors play major roles in the injury and repair responses in HPS, the ability of Gal-3 to interact with or alter the function of these moieties has not been evaluated. In this article, we demonstrate that Gal-3 accumulates in exaggerated quantities in bronchoalveolar lavage fluids, and traffics abnormally and accumulates intracellularly in lung fibroblasts and macrophages from bleomycin-treated pale ear, HPS-1-deficient mice. We also demonstrate that Gal-3 drives epithelial apoptosis when in the extracellular space, and stimulates cell proliferation and myofibroblast differentiation when accumulated in fibroblasts and M2-like differentiation when accumulated in macrophages. Biophysical and signaling evaluations also demonstrated that Gal-3 physically interacts with IL-13Rα2 and CHI3L1, and competes with TMEM219 for IL-13Rα2 binding. By doing so, Gal-3 diminishes the antiapoptotic effects of and the antiapoptotic signaling induced by CHI3L1 in epithelial cells while augmenting macrophage Wnt/β-catenin signaling. Thus, Gal-3 contributes to the exaggerated injury and fibroproliferative repair responses in HPS by altering the antiapoptotic and fibroproliferative effects of CHI3L1 and its receptor complex in a tissue compartment-specific manner.

Indexed as

AnimalsApoptosisbeta CateninBleomycinBronchoalveolar Lavage FluidCell DifferentiationCell ProliferationChitinase-3-Like Protein 1Epithelial CellsFibroblastsGalectin 3Hermanski-Pudlak SyndromeLungMacrophagesMiceMice, Inbred C57BLbeta CateninBleomycinChitinase-3-Like Protein 1Galectin 3

Identifiers

PMID29427412
PMCPMC5839999
OpenAlexW2786703147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.